Prolactin Levels During Long-Term Risperidone Treatment in Children and Adolescents
J Clin Psychiatry 2003;64:1362-1369
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: This analysis was designed to
investigate prolactin levels in children and adolescents on
long-term risperidone treatment and explore any relationship with
side effects hypothetically attributable to prolactin (SHAP).
Method: Data from 5 clinical trials
(total N = 700) were pooled for this post hoc analysis. Children
and adolescents aged 5 to 15 years with subaverage intelligence
quotients and conduct or other disruptive behavior disorders
received risperidone treatment (0.02-0.06 mg/kg/day) for up to 55
weeks. Outcome measures analyzed included serum prolactin levels,
reported adverse events, and the conduct problem subscore of the
Nisonger Child Behavior Rating Form.
Results: Mean prolactin levels rose from
7.8 ng/mL at baseline to a peak of 29.4 ng/mL at weeks 4 to 7 of
active treatment, then progressively decreased to 16.1 ng/mL at
weeks 40 to 48 (N = 358) and 13.0 ng/mL at weeks 52 to 55 (N =
42). There was no relationship between prolactin levels and age.
Females returned to a mean value within the normal range (< =
30 ng/mL) by weeks 8 to 12, and males were close to normal values
(< = 18 ng/mL) by weeks 16 to 24. At least 1 SHAP was reported
by 13 (2.2%) of 592 children. There was no direct correlation
between prolactin elevation and SHAP.
Conclusion: With long-term risperidone treatment
in children and adolescents, serum prolactin levels tended to
rise and peak within the first 1 to 2 months and then steadily
decline to values within or very close to the normal range by 3
to 5 months.